New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse ...
Mayo Clinic’s Chelsee Jensen, PharmD, discusses FDA policy changes, biosimilar development hurdles, denosumab lessons, and ...
The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to ...
A new study confirms KM118, a proposed biosimilar to pertuzumab, shows pharmacokinetic similarity and safety, paving the way for affordable HER2-positive breast cancer treatments.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD ...
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results